Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Asker Healthcare Group ABOSTO:ASKER -0.41%13 3-Year EBITDA Growth Rate is 14.70% as of Jun. 2026, which is at its 10-year median of 14.70. GuruFocus rates OSTO:ASKER with a GF Score™ of 13/100. The stock has 3 warning signs investors should review. Among 106 Medical Distribution companies, Asker Healthcare Group AB ranks better than 67.92% on this metric.
During the past 12 months, Asker Healthcare Group AB's average EBITDA Per Share Growth Rate was 4.60% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 14.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 4 years, the highest 3-Year average EBITDA Per Share Growth Rate of Asker Healthcare Group AB was 14.70% per year. The lowest was 14.70% per year. And the median was 14.70% per year.
Asker Healthcare Group AB (OSTO:ASKER) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Asker Healthcare Group AB 3-Year EBITDA Growth Rate Related Terms
OSTO:ASKER vs MCK, COR, CAH: 3-Year EBITDA Growth Rate Comparison
For the Medical Distribution subindustry, Asker Healthcare Group AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asker Healthcare Group AB 3-Year EBITDA Growth Rate vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Asker Healthcare Group AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Asker Healthcare Group AB's 3-Year EBITDA Growth Rate falls into.
Asker Healthcare Group AB 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 14.70% mean?
Asker Healthcare Group AB (OSTO:ASKER) has a 3-Year EBITDA Growth Rate of 14.70% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Asker Healthcare Group AB and its competitors. This is near median its historical median of 14.70. Over the past decade, Asker Healthcare Group AB's 3-Year EBITDA Growth Rate has ranged from 14.70 to 14.70. According to the industry distribution chart, Asker Healthcare Group AB ranks #34 out of 106 companies in the Medical Distribution industry, placing it in the top 32.1%.
Is Asker Healthcare Group AB's 3-Year EBITDA Growth Rate too high?
Asker Healthcare Group AB's current 3-Year EBITDA Growth Rate of 14.70% is near median its 10-year median of 14.70. Over the past 10 years, this metric has ranged from a low of 14.70 to a high of 14.70. The Medical Distribution industry median 3-Year EBITDA Growth Rate is 6.15. Asker Healthcare Group AB's value of 14.70% is 139% above this industry median. Based on the distribution chart, Asker Healthcare Group AB ranks #34 out of 106 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Asker Healthcare Group AB has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Asker Healthcare Group AB's 3-Year EBITDA Growth Rate compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Asker Healthcare Group AB ranks #34 out of 106 companies for 3-Year EBITDA Growth Rate. This puts Asker Healthcare Group AB in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 6.15. Asker Healthcare Group AB's value of 14.70% is 139% above this benchmark. Historically, Asker Healthcare Group AB's own 3-Year EBITDA Growth Rate has ranged from 14.70 to 14.70 over the past decade. While the company's 10-year median is 14.70 vs. the industry median of 6.15, Asker Healthcare Group AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Distribution company?
The median 3-Year EBITDA Growth Rate among Medical Distribution companies is 6.15, based on 106 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Asker Healthcare Group AB's current 3-Year EBITDA Growth Rate of 14.70% is 139% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Asker Healthcare Group AB and its competitors. For the Medical Distribution industry, the median 3-Year EBITDA Growth Rate is 6.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Asker Healthcare Group AB's current 3-Year EBITDA Growth Rate is 14.70%, which is near median its own 10-year median of 14.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asker Healthcare Group AB stock overvalued right now?
Asker Healthcare Group AB (OSTO:ASKER) has a current 3-Year EBITDA Growth Rate of 14.70%. The current 3-Year EBITDA Growth Rate is 14.70%, which is near median its 10-year median of 14.70 and 139% above the Medical Distribution industry median of 6.15. Asker Healthcare Group AB's overall GF Score™ is 13/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Asker Healthcare Group AB (OSTO:ASKER), the current 3-Year EBITDA Growth Rate is 14.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Asker Healthcare Group AB is a provider of medical products and solutions that drive progress in the European healthcare sector. The company is engaged in building and acquiring companies to support the healthcare system to improve patient outcomes, reduce the total cost of care, and ensure a fair and sustainable value chain. The company also offers a range of value-added solutions to support its suppliers and customers in, for example, market access, efficiency, and sustainability. Company has adapted a twin engine growth strategy that combines organic and acquired growth. Geographically, the company evaluates the operations in three business areas: North, West and Central.
13GF Score
Get the complete analysis for OSTO:ASKER
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ASKER has been successfully added to your 
